VAUGHAN, ON, Jan. 8, 2019 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company“, TSX: TRST), one of Canada’s leading, most trusted licensed producers of cannabis and the 2018 Canadian Cannabis Awards “Top Licensed Producer of the Year”, announces that it has applied to list its common shares on the New York Stock Exchange (the “NYSE“).

Listing of the Company’s common shares on the NYSE remains subject to the approval of the NYSE and the satisfaction of all applicable listing and regulatory requirements. In connection with the intended listing on the NYSE, the Company has filed a registration statement on Form 40-F (the “Registration Statement“) with the United States Securities and Exchange Commission (the “SEC“). The Registration Statement has not yet been declared effective by the SEC. Upon receipt of all required approvals and completion of the formal listing process, the Company will publicly announce its first trading date on the NYSE.
“CannTrust has firmly established itself as one of the top licensed producers in Canada with a global platform rooted in trust, science and innovation,” said Peter Aceto, CEO of CannTrust. “A listing on the NYSE is a natural step forward in our evolution as we look to broaden our investor base, increase the Company’s exposure and expand our business on an international scale.”
About CannTrustCannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry and serves over 57,000 medical patients with its dried, extract and capsule products. The Company operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility. The industry’s broadest product portfolio is prepared and packaged at the 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.
CannTrust is developing nanotechnology to develop new products in the medical, recreational, beauty, wellness and pet markets. The Company has established its international footprint through a strategic partnership with Cannatrek Ltd. in Australia and a joint venture with STENOCARE in Denmark. The Company has also partnered with Breakthru Beverage Group through Kindred Canada, for recreational distribution in Canada. CannTrust is committed to research and innovation. Its partnerships with McMaster University in Ontario and Gold Coast University in Australia were designed to contribute to the growing body of evidence-based research regarding the use and efficacy of cannabis.
Fundamentals
Market Capitalization, $K 828,490
Shares Outstanding, K 104,344
Annual Sales, $ 20,698 K
Annual Income, $ 6,885 K
36-Month Beta N/A
Price/Sales 13.58
Price/Cash Flow N/A
Price/Book 4.42
Price/Earnings ttm 39.70
Earnings Per Share ttm 0.20
Most Recent Earnings 0.00 on 09/30/18
CannTrust was proudly voted Top Licensed Producer of the Year at the 2018 Canadian Cannabis Awards. For more information, please visit www.canntrust.ca.

PLUS

These two marijuana stocks are making the move to the iconic NYSE

In 2019, the validation of the cannabis industry will continue. Within the past three weeks, two Canadian pot growers, HEXO (NASDAQOTH: HYYDF) and CannTrust Holdings(NASDAQOTH: CNTTF), have filed the paperwork needed to uplist their common stock from the over-the-counter (OTC) exchange to the New York Stock Exchange (NYSE).
Why uplist? The simple reason is that it demonstrates the legitimacy of the legal weed industry. By listing their shares side by side with other time-tested businesses on the NYSE, HEXO and CannTrust will be demonstrating not only that they meet the requirement to list on the iconic exchange, but also that their businesses offer the potential for growth over the long run.
In addition, listing on the NYSE will roll out the red carpet for institutional investors. Not all investment banks are willing to cover and/or invest in companies listed on the OTC exchange. By moving to the NYSE, HEXO and CannTrust will be far more welcoming to coverage from Wall Street firms and investment.
Mind you, this won't be the first rodeo for pot stocks on a major U.S. exchange. Before HEXO and CannTrust, which haven't been approved for NYSE listing yet, but are likely to be, in my view, Cronos Group uplisted to the Nasdaq, with Canopy Growth, Aurora Cannabis, and Aphria making the move to the NYSE.

CannTrust could bring something new to the NYSE


CannTrust, its secret to success is its growing method. CannTrust's Niagara and Vaughan facility rely on hydroponics, or the growth of plants in a nutrient-rich water solvent as opposed to soil. In CannTrust's case, it has access to low-cost water and electricity, which should lead to very promising yields and exceptionally low-cost production. At its peak, CannTrust should produce right around the same amount annually as HEXO.
The biggest wildcard for CannTrust is the third and final phase of its Niagara greenhouse expansion. Having completed 450,000 square feet already, the final 600,000 square feet of expansion has been held up by permitting issues. If CannTrust can quickly resolve these issues, it shouldn't have much problem turning an operating profit relatively soon. However, if this permitting issue drags on, CannTrust may opt for other capacity expansion options that aren't as cost-effective. It's something to closely monitor in 2019.